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Background: Fibrinogen is a marker of systemic inflammation and may be important in the 
pathogenesis and progression of chronic obstructive pulmonary disease (COPD).
Methods: We used baseline data from Atherosclerosis Risk in Communities and Cardiovascular 
Health Studies to determine the relation between fibrinogen levels and COPD and to examine 
how fibrinogen levels at baseline affected outcomes of death, development of COPD, lung 
function decline, and COPD-hospitalizations.
Results: Our study sample included 20,192 subjects, of whom 2995 died during the 
follow-up period. The mean fibrinogen level was 307.6 mg/dL and 10% of the sample had 
levels .393.0 mg/dL. Subjects with Stage 3 or 4 COPD were more likely to have a fibrinogen 
level .393.0 mg/dL (odds ratio 2.28, 95% confidence interval [CI]: 1.79–2.95). In the longitudinal 
adjusted models, fibrinogen levels .393 mg/dL predicted mortality (hazards ratio 1.54, 95% 
CI: 1.39–1.70), COPD-related hospitalization (hazards ratio 1.45, 95% CI: 1.27–1.67), and 
incident Stage 2 COPD (odds ratio 1.36, 95% CI: 1.07–1.74). Similar findings were seen with 
continuous fibrinogen levels.
Conclusion: In the Atherosclerosis Risk in Communities/Cardiovascular Health Studies cohort 
data, higher fibrinogen levels are predictors of mortality, COPD-related hospitalizations, and 
incident Stage 2 COPD.
Keywords: COPD, fibrinogen, epidemiology, mortality, hospitalization
Background
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with varied 
clinical presentations.1 COPD became the third leading cause of death in the United 
States in 2008.2 Approximately one in 20 deaths in the United States had COPD as the 
underlying cause.2 Understanding the natural history of COPD has been important in 
the field of pulmonary medicine, dating back to the work of Burrows et al,3 and Fletcher 
et al.4 Over subsequent years researchers have championed different hypotheses about 
COPD development, including the British hypothesis stating that the presence of cough 
and sputum was the key factor5 and the Dutch hypothesis stating that the presence of 
increased airways responsiveness was the major factor.6
Fibrinogen is an inflammatory marker that is increased in COPD, as well as many 
other inflammation-associated diseases.7 The Coronary Artery Risk Development 
in Young Adults CARDIA study showed fibrinogen as a marker for chronic low-
grade inflammation and is associated with modest deterioration of lung function 
in healthy young adults.8 According to Dahl and colleagues, increased levels of 
fibrinogen were associated with reduced lung function and increased risk of COPD, 
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and these  associations were independent of smoking status.9 
 Groenewegen and colleagues demonstrated that besides lung 
function impairment systemic inflammation manifested by 
elevated fibrinogen levels was an independent risk factor for 
exacerbations of COPD.10 Hyperfibrinogenemia is linked 
with asthma11 and smoking.12 There is little information on 
the relationship between plasma fibrinogen levels and lung 
function decline;8 although recent work has suggested that 
systemic processes may be important in these processes.
We hypothesized that fibrinogen can be used as a tool 
for stratifying COPD patients in clinical trials by identifying 
populations at higher risk for poor outcomes such as devel-
opment of COPD, rapidly declining lung function, COPD 
hospitalizations, and death. This paper examines the descrip-
tors of normal and elevated fibrinogen levels at baseline in a 
cohort of US adults and determines the relationship between 
elevated fibrinogen levels and incident respiratory outcomes 
including development of COPD, rapidly declining lung 
function, COPD hospitalizations, and death controlling other 
risk factors, including cardiovascular disease (CVD).
Methods
Study population
The study population originated from the combined cohorts 
of the Atherosclerosis Risk in Communities (ARIC) and 
Cardiovascular Health Study (CHS). Both the ARIC and CHS 
were population-based National Institute of Health cohorts 
initiated in the late 1980s.
The ARIC study was initiated in 1987 as a longitudinal, 
population-based study of the etiology and clinical sequelae of 
atherosclerosis in 15,792 adults. Study protocols were approved 
for protection of human subjects. Participants were selected 
from the entire population by probability sampling from 
four US communities: Forsyth County, NC; Minneapolis, 
MN; Washington County, MD; and Jackson, MS (where 
only  African Americans were sampled). Specific details 
of the ARIC study are published elsewhere.13 Our analysis 
was limited to ARIC participants aged 45–64 years old at 
baseline, who provided information on respiratory symptoms 
and diagnoses, medical history, and who underwent adequate 
pulmonary function testing at the baseline examination.
The original CHS cohort consisted of 5201 subjects 
selected using Medicare eligibility lists provided by the US 
Healthcare Financing Administration for four communities: 
Forsyth County, NC; Pittsburgh, PA; Sacramento County, 
CA; and Washington County, MD from May 1989 to 
May 1990. Analysis was limited to subjects who provided 
information on respiratory symptoms and diagnoses, medical 
history, and smoking status, and who underwent a clinical 
exam and spirometric testing at baseline and 4 years. Details 
of the CHS are published elsewhere.14
Definition of variables
Demographic data used in this analysis were age (in 5 year 
categories for ARIC and 4 year categories for CHS), sex, race 
(black, white, other), education (less than 12 years, 12 years, and 
more than 12 years). The study participants were categorized 
into normal and elevated fibrinogen values with a cut off value 
of greater than 393 mg/dL (corresponding to the top decile) 
and six lung function categories based on  modified Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
 criteria; classification is based on “pre-bronchodilator” 
response. GOLD Stage 3 or 4 (forced expiratory volume 
in 1 second (FEV
1
)/forced vital capacity (FVC) ,0.70 and 
FEV
1





 .50 to ,80% predicted), GOLD Stage 1 (FEV
1
/
FVC ,0.70 and FEV
1
 .80%), restricted (FEV
1
/FVC .0.70 
and FVC ,80% predicted), GOLD Stage 0 (presence of 
respiratory symptoms in the absence of any lung function 
abnormality), and no lung disease.
We included in the analyses potential confounders 
of CVD at baseline (subjects reporting a diagnosis of a 
previous myocardial infarction, stroke, heart failure, angina 
or transient ischemic attack, and excluding hypertension). 
Smoking status included current, former, and never smokers. 
Respondents with a positive response to “Have you ever 
smoked cigarettes?” and “Do you now smoke cigarettes?” 
were classified as “ever smokers” and “current smokers,” 
respectively. Pipe or cigar smokers were also considered 
as “smokers.” Subjects were classified as having diabetes 
if they reported either a diagnosis of diabetes at baseline or 
had impaired fasting or post-glucose load levels (140 mg/dL) 
upon examination. Body mass index was categorized as 
“Underweight” (,20), “Normal” (20–24), “Overweight” 
(25–29), and “Obese” (30).
Laboratory methods – fibrinogen
In ARIC, blood was drawn after an 8-hour fasting 
period with minimal trauma from an antecubital vein. 
Samples were processed by a standardized protocol and 
stored at -70°C until assayed at the ARIC Hemostasis 
Laboratory at the University of Texas Medical School, 
Houston, TX. Detailed methods for blood processing 
and measurement of hemostatic variables have been 
published elsewhere.15  Fibrinogen was measured by the 
thrombin-time titration method.16 Reliability  coefficients 
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obtained from repeated testing of individuals over several 
weeks were 0.72 for fibrinogen.16
In CHS, baseline fibrinogen levels in 1989–1990 were 
measured with a BBL fibrometer (Becton Dickinson, 
 Cockeysville, MD) by the Clauss methods with Dade fibrino-
gen calibration reference (Baxter-Dade, Bedford, MA) and 
bovine thrombin (Parke-Davis, Lititz, PA).17
Pulmonary function testing
In both studies, spirometry was conducted using a volume 
displacement, water-sealed spirometer. At least three accept-
able spirograms were obtained from a minimum of five 
forced expirations. The best single spirogram was identi-
fied by computer and confirmed by a technician. Quality 
assurance was provided by the CHS Pulmonary Function 
Center for CHS and the ARIC investigators for ARIC, and 
the procedures followed contemporary American Thoracic 
Society guidelines.18 Several measures of lung function were 
used in this analysis: the FEV
1
, the FVC, and the FEV
1
/FVC 
ratio. We used the prediction equations derived from the 
Third National Health and Nutrition Examination Survey to 
define the predicted values of FEV
1
 and FVC.19 We defined 
a subject as having a respiratory symptom if they reported 
cough, phlegm, dyspnea, or wheeze.
Definition of outcomes
Death was defined as all-cause mortality. COPD-related 
hospitalizations were people with hospitalization code of 
ICD-9 490–496 at any time after baseline. Rapidly declining 
lung function comprised of people who, between the first and 
second spirometries, were in the highest quartile of FEV
1
 
decline (determined as an absolute difference in the baseline 
minus the follow-up FEV
1
 and divided by the interval between 
the two tests to obtain FEV
1
 loss per year). Lung function 
decline was also determined as a proportion of the baseline 
FEV
1
 and relative to the predicted FEV
1
 at baseline, but only 
the absolute difference was used in the analyses. We also 
determined the proportion of people who were unable to 
obtain a follow-up spirometry. The development of COPD 
was defined as GOLD Stage 2 or higher disease in people who 
at baseline did not have GOLD Stage 2 or higher disease.
Statistical analyses
Data analysis was completed with SAS (v 9.2; SAS Institute, 
Cary, NC) and SUDAAN (v 9.0; RTI, Research Triangle 
Park, NC). Descriptive statistics and frequency distributions 
were calculated for the studied population and its relationship 
to fibrinogen levels and predictors (GOLD Status, CVD, 
smoking status, diabetes mellitus). Linear regression model 
using SUDAAN procedure REGRESS was used to deter-
mine correlates of fibrinogen levels controlling for age, sex, 
race/ethnicity, body mass index, smoking status, modified 
GOLD stage, diabetes, CVD, and educational level. These 
were replicated examining fibrinogen levels in the top decile 
(.393.0 mg/dL) using the SUDAAN procedure RLOGIST, 
controlling for these same potential confounders. Our primary 
outcome of interest in the survival models was time to death 
and COPD-related hospitalization. Cox proportional hazard 
regression models were developed using the SUDAAN pro-
cedure SURVIVAL to account for differential follow-up in 
cohort participants. (Censoring occurred at the date of death 
on certificate or the date the participant was last known to 
be alive for mortality, and date of hospitalization or date last 
known to be alive for COPD-related hospitalization.) The 
SUDAAN procedure RLOGIST was used to determine the 
relation between fibrinogen levels and elevated fibrinogen lev-
els and not having a follow-up spirometry, being in the highest 
quartile of FEV
1
 decline, and having incident COPD.
Results
The combined cohorts of ARIC and CHS included 20,993 
participants at baseline. We excluded 311 who had not 
obtained fibrinogen levels, 209 who did not have pulmo-
nary function testing done, and 281 subjects missing other 
key baseline data leaving 20,192 subjects in the combined 
cohorts. The mean follow-up time was 9.7 years, with a 
maximum of 12.1 years. By the end of the follow-up time, 
2995 subjects (14.8%) had died.
Table 1 shows the distribution of age, sex, race/ethnicity, 
body mass index, smoking status, modified GOLD stage, 
diabetes mellitus, CVD, and educational level, including the 
actual numbers of studied subjects and the percentage. This 
Table also reports the mean fibrinogen levels, the proportion 
of subjects with fibrinogen levels .393.0 mg/dL, and the 
deaths per 1000 person-years of follow-up.
Tables 2 and 3 report the correlates of fibrinogen levels 
(Table 2) and the correlates of elevated fibrinogen levels 
(Table 3). There was considerable overlap between these 
two analyses; for example, in both analyses older age, 
 current smoking, and the presence of diabetes or CVD 
were associated with higher fibrinogen levels. The presence 
of severe or very severe COPD was one of the strongest 
predictors of fibrinogen levels, with a mean increase of 
24.71 mg/dL (standard error 3.13 mg/dL) in the linear 
regression models and an odds ratio for elevated fibrinogen 
of 2.28 (95%  confidence interval: 1.79–2.95).
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Table 4 shows the proportion of participants with the 
outcomes of interest. During follow-up, 14.8% of the cohort 
died, 7.5% experienced a COPD-related hospitalization, 
and 16.3% did not obtain a follow-up spirometry. The 
table also shows 16,935 subjects had a follow-up spirometry 
and of these, 14,848 did not have Stage 2 or higher COPD 
at  baseline. Of the latter, 4.9% were found to have Stage 2 
or higher COPD in follow-up.
The quartiles of lung function change are displayed in 
Table 5. The most rapidly declining quartile lost 127 mL 
of FEV
1
 annually, corresponding to 4.7% (annually) 
of their baseline value and 4.3% of their predicted 
baseline value.
Table 6 displays the unadjusted and fully adjusted models 
for either continuous fibrinogen or elevated fibrinogen 
(.393 mg/dL) predicting death, COPD-related hospitalization, 
missing spirometry, rapidly declining lung function, and 
incident COPD. Fibrinogen was a significant predictor of all 




Table 1 Demographic characteristics and fibrinogen levels of subjects included in the analysis
Covariate n % Mean fibrinogen level in  
mg/dL (standard error)
Proportion with  
fibrinogen .393.0 mg/dL
Deaths per  
1000 person years
Age
 45–49 4072 20.2 292.5 (1.0) 6.6 3.8
 50–54 3968 19.7 301.1 (1.0) 8.5 6.3
 55–59 3739 18.5 308.6 (1.1) 9.5 10.7
 60–64 3507 17.4 313.2 (1.1) 10.6 17.6
 65–68 1279 6.3 316.0 (1.1) 11.6 18.3
 69–72 1465 7.3 319.8 (1.7) 13.9 26.0
 73–76 973 4.8 318.9 (1.9) 12.5 37.0
 77–80 690 3.4 324.0 (2.6) 15.5 60.0
  .80 499 2.5 333.9 (4.8) 18.2 108.5
Sex
 Male 9011 44.6 302.9 (0.7) 9.2 19.8
 Female 11,181 55.4 311.4 (0.6) 10.5 11.8
Race-ethnicity
 White 16,027 79.4 304.1 (0.5) 8.7 15.4
 Black 4165 20.6 321.0 (1.1) 14.9 15.0
Body mass index
  ,20 800 4.0 301.9 (2.5) 9.6 28.2
 20–25 6263 31.0 297.7 (0.8) 7.7 15.2
 25–30 8073 40.0 305.8 (0.7) 9.1 15.1
  .30 5056 25.0 323.8 (1.0) 14.2 13.7
Smoking status
 Current smoker 4929 24.4 323.4 (1.0) 14.2 18.6
 Former smoker 7036 34.9 302.1 (0.8) 8.9 16.9
 never smoker 8227 40.7 303.0 (0.7) 8.2 12.0
Modified GOLD stage
 Stage 3 or 4 585 2.9 336.8 (3.1) 19.3 54.6
 Stage 2 2221 11.0 320.7 (1.5) 14.1 25.3
 Stage 1 2669 13.2 309.5 (1.3) 11.3 23.2
 Symptoms only 4375 21.7 306.0 (1.0) 14.0 13.2
 Restrictive 3071 15.2 324.2 (1.3) 9.3 15.8
 none 7271 36.0 294.6 (0.7) 6.1 8.2
Diabetes mellitus
 Yes 2519 12.5 328.3 (1.5) 16.8 32.6
 no 17,673 87.5 304.7 (0.5) 9.0 13.1
Cardiovascular disease
 Yes 3076 15.3 320.4 (1.3) 14.0 33.3
 no 17,116 84.8 305.3 (0.5) 9.2 12.4
Education level
  ,12 4937 24.5 322.1 (1.0) 14.1 24.3
 12 years 6366 31.5 307.0 (0.8) 9.5 12.4
  .13 years 8889 44.0 300.0 (0.8) 7.9 12.7
Total 20,192 100.0 307.6 (0.5) 9.9 15.1
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Figures 1–3 depict the interaction between fibrinogen 
levels .393 mg/dL and modified GOLD stage in predicting 
mortality, COPD-related hospitalization, and incident COPD.
Discussion
This analysis determined that fibrinogen levels were related 
to spirometrically determined obstructive lung disease, with 
evidence of a dose-response effect for COPD. Subjects with 
more advanced COPD (Stages 3 or 4) had a greater eleva-
tion in fibrinogen (24.71 mg/dL, P = 0.0000) than GOLD 
Stage 2 or GOLD Stage 1 disease (12.04 mg/dL, P = 0.0000 
and 7.68 mg/dL, P = 0.0000 respectively), relative to people 
with normal lung function. In addition, we determined that 
higher fibrinogen levels were related to an increased risk of 
death, COPD-related hospitalization, and the development 
of COPD.
Table 2 Correlates of fibrinogen levels from linear regression 
models (n = 20,192)






 45–49 0 0
 50–54 7.60 1.32 ,0.001
 55–59 14.82 1.39 ,0.001
 60–64 19.06 1.43 ,0.001
 65–68 25.71 1.97 ,0.001
 69–72 30.90 1.95 ,0.001
 73–76 31.74 2.21 ,0.001
 77–80 38.02 2.83 ,0.001
  .80 51.44 3.51 ,0.001
Sex
 Male -7.36 1.01 ,0.001
 Female 0 0
Race-ethnicity
 White 0 0
 Black 15.39 1.24 ,0.001
Body mass index
  ,20 -5.88 2.47 0.017
 20–25 0 0
 25–30 9.58 1.04 ,0.001
  .30 24.63 1.24 ,0.001
Smoking status
 Current smoker 25.60 1.23 ,0.001
 Former smoker 1.64 1.04 0.116
 never smoker 0 0
GOLD stage
 Stage 3 or 4 24.71 3.13 ,0.001
 Stage 2 12.04 1.66 ,0.001
 Stage 1 7.68 1.48 ,0.001
 Symptoms only 15.44 1.47 ,0.001
 Restrictive 3.05 1.17 0.009
 none 0 0
Diabetes mellitus
 Yes 11.22 1.55 ,0.001
 no 0 0
Cardiovascular disease
 Yes 8.19 1.34 ,0.001
 no 0 0
Education level
  ,12 7.46 1.21 ,0.001
 12 years 3.90 1.01 ,0.001
  .13 years 0 0
Table 3 Correlates of fibrinogen levels .393 mg/dL (top decile) 
from logistic regression models (n = 20,192)
Covariate Odds ratio 95% confidence 
interval
Age
 45–49 1.00 1.00
 50–54 1.30 (1.09, 1.54)
 55–59 1.42 (1.19, 1.68)
 60–64 1.62 (1.36, 1.93)
 65–68 2.01 (1.59, 2.53)
 69–72 2.67 (2.16, 3.30)
 73–76 2.44 (1.90, 3.14)
 77–80 3.29 (2.51, 4.29)
  .80 4.48 (3.36, 5.98)
Sex
 Male 0.93 (0.83, 1.04)
 Female 1.00 1.00
Race-ethnicity
 White 1.00 1.00
 Black 1.99 (1.77, 2.24)
Body mass index
 ,20 0.97 (0.74, 1.26)
 20–25 1.00 1.00
 25–30 1.23 (1.08, 1.40)
  .30 1.91 (1.67, 2.19)
Smoking status
 Current smoker 2.12 (1.86, 2.41)
 Former smoker 1.16 (1.02, 1.31)
 never smoker 1.00 1.00
GOLD stage
 Stage 3 or 4 2.28 (1.79, 2.95)
 Stage 2 1.77 (1.52, 2.14)
 Stage 1 1.59 (1.34, 1.88)
 Symptoms only 1.77 (1.55, 2.13)
 Restrictive 1.23 (1.07, 1.44)
 none 1.00 1.00
Diabetes mellitus
 Yes 1.47 (1.29, 1.67)
 no 1.00 1.00
Cardiovascular disease
 Yes 1.29 (1.14, 1.46)
 no 1.00 1.00
Education level
  ,12 1.26 (1.11, 1.42)
 12 Years 1.18 (1.05, 1.33)
  .13 years 1.00 1.00
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Table 4 Proportion of subjects with the outcome of interest: death, any COPD-related hospitalization during follow-up, those missing 






Missing follow-up  
spirometry 
n = 20,192
Highest quartile  
of FEV1 decline 
n = 16,935
Incident  
Stage 2 COPD 
n = 14,848
Age
 45–49 3.9 1.1 10.5 24.4 2.7
 50–54 6.4 2.4 10.3 26.1 3.1
 55–59 10.6 4.4 10.9 26.6 4.4
 60–64 16.9 7.9 14.1 27.9 5.4
 65–68 17.8 15.6 21.8 22.4 8.9
 69–72 24.4 18.4 25.7 21.9 9.2
 73–76 33.0 20.4 31.9 19.9 10.5
 77–80 48.1 22.9 40.7 18.8 13.7
  .80 72.1 19.4 60.1 18.8 10.7
Sex
 Male 11.7 6.0 15.8 18.6 4.5
 Female 18.8 9.3 16.8 33.3 5.3
Race-ethnicity
 White 14.9 8.6 14.9 26.1 5.4
 Black 14.5 3.2 21.5 21.1 3.1
Body mass index
  ,20 25.8 15.3 23.0 22.5 7.9
 20–25 14.8 7.9 16.0 24.6 5.7
 25–30 14.7 6.9 15.2 26.2 4.7
  .30 13.4 6.6 17.2 24.4 4.0
Smoking status
 Current smoker 17.8 12.3 19.2 31.0 8.6
 Former smoker 16.3 8.7 16.1 26.3 5.1
 never smoker 11.8 3.6 14.7 20.8 2.9
GOLD stage
 Stage 3 or 4 44.8 46.5 38.3 19.6 n/A
 Stage 2 23.5 19.6 23.5 25.5 n/A
 Stage 1 21.6 10.6 19.6 31.7 15.0
 Symptoms only 13.0 4.3 14.4 27.0 2.6
 Restrictive 15.3 6.5 19.2 13.4 8.3
 none 8.2 1.8 11.0 26.6 1.6
Diabetes mellitus
 Yes 29.0 10.3 27.0 23.5 5.9
 no 12.8 7.1 14.7 25.3 4.8
Cardiovascular disease
 Yes 29.6 15.8 25.7 27.9 7.5
 no 12.2 6.0 14.6 24.7 4.5
Education level
  ,12 22.6 11.8 25.7 23.4 5.8
 12 years 12.1 6.9 14.3 24.8 5.1
  .13 years 12.5 5.4 12.5 26.2 4.3
Fibrinogen .393
 Yes 28.5 14.8 29.1 25.3 8.4
 no 13.3 6.7 14.9 25.1 4.6
 Total 14.8 7.5 16.3 25.1 4.9
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
Our findings are consistent with those of Dahl et al9 
who showed that increased levels of plasma fibrinogen 
were associated with reduced lung function and increased 
risk of COPD, independent of smoking status. Jiang et al20 
also found that higher levels of baseline fibrinogen were 
 cross-sectionally associated with lower lung function and 
greater longitudinal declines in FEV
1
/FVC ratio in the 
elderly. Two population based studies21,22 showed that 
stable COPD patients have a pro-inflammatory state with 
increased levels of acute-phase reactants. Kalhan et al8 found 
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that participants in the highest year 7 fibrinogen had greater 
FEV
1
 and FVC decline.
This analysis demonstrates that fibrinogen levels in this 
cohort were significantly related to a number of factors, 
including age, sex, race/ethnicity, current smoking status, 
overweight and obesity, presence of chronic diseases such 
as CVD, diabetes mellitus, and COPD. A previous study22 
has shown that obstructive and restrictive lung diseases 
were predictors of increased levels of plasma fibrinogen. As 
fibrinogen levels were only determined at baseline we can-
not speculate whether elevated fibrinogen caused COPD or 
COPD caused elevated levels of fibrinogen. It is still unknown 
and uncertain how and why individuals with COPD develop 
systemic inflammation. Whatever is the mechanism of COPD 
development, previous studies have shown individuals with 
accelerated decline in lung function are at an increased risk of 
COPD hospitalizations in the future. Engstrom et al showed 
increased incidence of hospital admissions for COPD in those 
with raised fibrinogen.23
We have demonstrated an effect of elevated  fibrinogen 
on mortality, COPD-hospitalizations, and incident Stage 2 
COPD in the overall cohort (Table 6). The finding of elevated 
Table 5 Quartiles of lung function decline among subjects who had baseline and follow-up pulmonary function measurement (n = 16,935) 
and baseline FEV1, the mean annualized change in their absolute FEV1, annualized FEV1 change as a percentage of the baseline value, and 
annualized FEV1 change as a percentage of the baseline predicted FEV1 value
FEV1 change 
quartiles
n Baseline FEV1  
(percent predicted)
Change in FEV1  
(SD)
Change in FEV1 as  
percentage of baseline (SD)
Change in FEV1 as  
percentage of predicted (SD)
1 4322 98.1 -127 (63) -4.7 (2.6) -4.3 (2.2)
2 4306 93.9 -61 (10) -2.4 (0.9) -2.2 (0.5)
3 4307 91.2 -28 (9) -1.2 (0.6) -1.0 (0.4)
4 4310 88.0 33 (72) 1.9 (6.0) 1.2 (2.8)
Abbreviations: FEV1, forced expiratory volume in 1 second; SD, standard deviation.
Table 6 Results of unadjusted and fully adjusted logistic and Cox proportional hazards models predicting death, any COPD-related 
hospitalization during follow-up, those missing follow-up spirometry, highest quartile of FEV1 decline, and incident Stage 2 or higher 
COPD (among those free of COPD at baseline), with fibrinogen (per 100 mg/dL increase) or fibrinogen .393 mg/dL as the main 
predictors
Outcome Risk per 100 mg/dL  
increase in fibrinogen  
(unadjusted)
Risk per 100 mg/dL  
increase in fibrinogen  
(adjusted)*
Risk among subjects  
with fibrinogen  
levels .393 mg/dL  
(unadjusted)
Risk among subjects 
with fibrinogen  
levels .393 mg/dL  
(adjusted)*
Death 
n = 20,192 
Hazard ratio  
(95% confidence interval)
1.69 (1.62, 1.77) 1.31 (1.24, 1.38) 2.39 (2.18, 2.62) 1.54 (1.39, 1.70)
COPD-related hospitalization  
n = 20,192 
Hazard ratio  
(95% confidence interval)
1.76 (1.66, 1.87) 1.30 (1.21, 1.39) 2.52 (2.22, 2.87) 1.45 (1.27, 1.67)
Missing follow-up spirometry 
n = 20,192 
Odds ratio  
(95% confidence interval)
1.67 (1.58, 1.76) 1.25 (1.18, 1.33) 2.35 (2.12, 2.61) 1.52 (1.35, 1.71)
Highest quartile of  
FEV1 decline 
n = 16,935 
odds ratio  
(95% confidence interval)
1.00 (0.95, 1.06) 1.07 (1.01, 1.14) 1.01 (0.89, 1.14) 1.08 (0.95, 1.23)
Incident Stage 2 COPD 
n = 14,848 
Odds ratio  
(95% confidence interval)
1.49 (1.34, 1.65) 1.17 (1.03, 1.33) 1.90 (1.52, 2.38) 1.36 (1.07, 1.74)
Note: *Adjusted for age, sex, race, education level, body mass index, smoking status, diabetes mellitus, cardiovascular disease, and GOLD stage.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
































Figure 1 Risk of mortality by modified GOLD stage and elevated fibrinogen level.





























Figure 2 Risk of chronic obstructive pulmonary disease-related hospitalization by modified GOLD stage and elevated fibrinogen level.
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CHS, Cardiovascular Health Study; GOLD, Global Initiative on Chronic Obstructive Lung Disease.
f ibrinogen and the higher risk of mortality, COPD-
 hospitalizations, and incident Stage 2 COPD raises an 
option that fibrinogen could be used as a biomarker of 
 disease activity in COPD and potential target for therapeutic 
interventions.
To our knowledge, this is one of the few studies with 
follow-up data, and although fibrinogen level was only 
available at baseline, partial temporal association of 
fibrinogen and lung function can be taken into account, 
although other cohort studies with lung specimens, exac-
erbations, and imaging are needed to validate the findings. 
The study has adequate sample size and power. Bias due 
to investigator’s knowledge of disease or risk factor seems 
unlikely since plasma fibrinogen was measured without the 
knowledge of lung function test results or disease status 
of subjects.
This analysis has several limitations. Analysis was 
only done using baseline fibrinogen levels, as follow-up 
fibrinogen levels were not available on all subjects. Another 
limitation is the unavailability of post-bronchodilator lung 
function- measurement, information on COPD exacerbations 
other than hospitalized exacerbations, and lung imaging 
for COPD. Not all subjects completed pulmonary function 
testing, biasing our sample towards a healthier population. 
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In addition, although we have adjusted for potential con-
founders there remains residual confounding due to COPD 
disease pathology based on genetic constitution, nutritional 
intake, environmental exposures, alcohol intake, and other 
infections causing systemic inflammation. These findings 
need to be replicated in other cohorts, including those with 
longitudinal measurements of fibrinogen.
Conclusion
In conclusion, we have demonstrated that elevated plasma 
fibrinogen was associated with COPD; predicting higher risk 
of mortality, COPD-hospitalizations, and incident Stage 2 
disease. Fibrinogen can serve as a biomarker of the systemic 
component of COPD and may provide an option for target-
ing of interventions to patients with evidence of systemic 
inflammation or provide a means of stratifying patients in 
clinical trials. Future research is needed to evaluate whether 
targeted reduction in plasma fibrinogen levels will result in 
better COPD outcomes.
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